Lionhunter Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Lionhunter Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.45M	Buy	+400,245	New	+$2.61M	1.1%	29

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Lionhunter Capital Management's VNDA Position: Q2 2026 in Review

Lionhunter Capital Management opened a new position in Vanda Pharmaceuticals (VNDA) in Q2 2026: 400,245 shares worth $2.45M. The stake represents 1.1% of the portfolio and ranks #29 among its holdings.

158 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

Lionhunter Capital Management held 400,245 shares of Vanda Pharmaceuticals worth $2.45M as of Q2 2026.
Vanda Pharmaceuticals was a new Lionhunter Capital Management position in Q2 2026.
Vanda Pharmaceuticals made up 1.1% of Lionhunter Capital Management's portfolio in Q2 2026, its #29 holding.
158 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Lionhunter Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.